184 related articles for article (PubMed ID: 37068267)
21. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry.
Armaroli G; Klein A; Ganser G; Ruehlmann MJ; Dressler F; Hospach A; Minden K; Trauzeddel R; Foeldvari I; Kuemmerle-Deschner J; Weller-Heinemann F; Urban A; Horneff G
Arthritis Res Ther; 2020 Oct; 22(1):258. PubMed ID: 33121528
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
[TBL] [Abstract][Full Text] [Related]
23. Approach to switching biologics in juvenile idiopathic arthritis: a real-life experience.
Karadağ ŞG; Demirkan FG; Koç R; Çakmak F; Sönmez HE; Aktay Ayaz N
Rheumatol Int; 2022 Jan; 42(1):141-147. PubMed ID: 33846863
[TBL] [Abstract][Full Text] [Related]
24. The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis.
Cakan M; Ayaz NA; Karadag SG; Tanatar A
North Clin Istanb; 2020; 7(2):118-123. PubMed ID: 32259032
[TBL] [Abstract][Full Text] [Related]
25. Biotherapy in juvenile idiopathic arthritis Moroccan patients: a single-center experience.
Bouayed K; Hamraoui D; Mikou N; Sakhi A; Hilmi W
Pan Afr Med J; 2022; 41():135. PubMed ID: 35519160
[TBL] [Abstract][Full Text] [Related]
26. Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factor-negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication.
Aquilani A; Marafon DP; Marasco E; Nicolai R; Messia V; Perfetti F; Magni-Manzoni S; De Benedetti F
J Rheumatol; 2018 Jul; 45(7):956-961. PubMed ID: 29717035
[TBL] [Abstract][Full Text] [Related]
27. Biotechnological therapeutic in Juvenile Idiopathic Arthritis: Pathophysiological implications and targeted therapies.
Pinto AM; Ascenção I; Rodrigues M; Brito I
ARP Rheumatol; 2023; 2(4):299-306. PubMed ID: 38174749
[TBL] [Abstract][Full Text] [Related]
28. The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data.
Davies R; De Cock D; Kearsley-Fleet L; Southwood T; Baildam E; Beresford MW; Foster HE; Thomson W; Ramanan AV; Hyrich KL;
Rheumatology (Oxford); 2020 Jun; 59(6):1391-1397. PubMed ID: 31605484
[TBL] [Abstract][Full Text] [Related]
29. Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry.
Mannion ML; Xie F; Horton DB; Ringold S; Correll CK; Dennos A; Beukelman T;
J Rheumatol; 2021 Aug; 48(8):1322-1329. PubMed ID: 32934124
[TBL] [Abstract][Full Text] [Related]
30. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
31. Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study.
Grazziotin LR; Currie G; Twilt M; Ijzerman MJ; Kip MMA; Koffijberg H; Benseler SM; Swart JF; Vastert SJ; Wulffraat NM; Yeung RSM; Marshall DA
Pediatr Rheumatol Online J; 2022 Apr; 20(1):25. PubMed ID: 35410419
[TBL] [Abstract][Full Text] [Related]
32. Outcome Monitoring and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis.
Buckley L; Ware E; Kreher G; Wiater L; Mehta J; Burnham JM
J Rheumatol; 2020 Feb; 47(2):273-281. PubMed ID: 31308202
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of tofacitinib in the treatment of refractory cases of polyarticular course juvenile idiopathic arthritis: A study from Bangladesh.
Rahman MM; Laila K; Rahman SA
Int J Rheum Dis; 2022 Jun; 25(6):678-684. PubMed ID: 35435319
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.
Horneff G; Burgos-Vargas R; Constantin T; Foeldvari I; Vojinovic J; Chasnyk VG; Dehoorne J; Panaviene V; Susic G; Stanevica V; Kobusinska K; Zuber Z; Mouy R; Rumba-Rozenfelde I; Breda L; Dolezalova P; Job-Deslandre C; Wulffraat N; Alvarez D; Zang C; Wajdula J; Woodworth D; Vlahos B; Martini A; Ruperto N;
Ann Rheum Dis; 2014 Jun; 73(6):1114-22. PubMed ID: 23696632
[TBL] [Abstract][Full Text] [Related]
35. Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching.
Brunelli JB; Silva CA; Pasoto SG; Saa CGS; Kozu KT; Goldenstein-Schainberg C; Leon EP; Vendramini MBG; Fontoura N; Bonfa E; Aikawa NE
Clin Rheumatol; 2020 Feb; 39(2):515-521. PubMed ID: 31707543
[TBL] [Abstract][Full Text] [Related]
36. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
37. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
Yue X; Huang B; Hincapie AL; Wigle PR; Qiu T; Li Y; Morgan EM; Guo JJ
Paediatr Drugs; 2021 Mar; 23(2):171-182. PubMed ID: 33651370
[TBL] [Abstract][Full Text] [Related]
38. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
[TBL] [Abstract][Full Text] [Related]
39. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
40. High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy.
Mor-Vaknin N; Rivas M; Legendre M; Mohan S; Yuanfan Y; Mau T; Johnson A; Huang B; Zhao L; Kimura Y; Spalding SJ; Morris PW; Gottlieb BS; Onel K; Olson JC; Edelheit BS; Shishov M; Jung LK; Cassidy EA; Prahalad S; Passo MH; Beukelman T; Mehta J; Giannini EH; Adams BS; Lovell DJ; Markovitz DM
Arthritis Rheumatol; 2018 Apr; 70(4):594-605. PubMed ID: 29287303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
